Discover

News & Info

Quote List Quote List

LIVZON PHARMA(01513.HK)

Event Tracking

Mar26

Lizhu Pharmaceutical Subsidiary Granted Clinical Trial Approval for Injectable Brexpiprazole Microsphere

11:14

Mar24

LIVZON PHARMA released FY2025 earnings on March 24 After-Market BJT, actual revenue HKD 13.14 B (forecast HKD 13.54 B), actual EPS HKD 2.476 (forecast HKD 2.5931)

11:00

LIVZON PHARMA released FY2025 Q4 earnings on March 24 After-Market (BJT), actual revenue HKD 3.23 B (forecast HKD 3.129 B), actual EPS HKD 0.3399 (forecast HKD 0.4164)

11:00

Mar17

LIVZON PHARMA to release FY2025 earnings on March 24, pre-market BJT, forecast revenue HKD 13.7 B, EPS HKD 2.5931

00:06

Jan7

Lizhu Group's Subsidiary and Beijing XinKanghe Jointly Developed Lekangqita Monoclonal Antibody Injection Included in Priority Review List

09:46

Dec30

Lizhu Pharmaceutical Extends Equity Transfer Deadline for Acquisition of Vietnamese Listed Company Imexpharm Corporation to June 30, 2026

14:14

Schedules & Filings

Schedules

Filings

Mar24

Earning Release(CST)

FY2025 Q4 Earning Release (HKD) Revenue 3.23 B, Net Income 299.3 M, EPS 0.3372

Oct23

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 3.109 B, Net Income 517.08 M, EPS 0.5788

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 3.384 B, Net Income 705.29 M, EPS 0.7878

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More